Back

Rivaroxaban or warfarin in atrial fibrillation and coronary stent implantation in real-world patients involving chronic kidney disease (REWRAPS): 5-year follow-up study

2 September 2024 (11:00 - 11:50)
Organised by: Logo
Congress Presentation Part of: Data-driven decisions for anticoagulant and antiplatelet therapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Yukio Ozaki

Fujita Health University Okazaki Medical Center, Aichi (Japan)

7 More presentations in this session

Presentation thumbnail
Comparative discontinuation and non-bleeding side effects of Clopidogrel, Prasugrel and Ticagrelor in patients with acute coronary syndromes; a Network Meta-analysis of Randomized Controlled Trials
Doctor S. Yanko (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Anticoagulant monotherapy versus anticoagulant therapy in combination with single antiplatelet agent in patients after coronary artery bypass grafting - analysis of real-world data
Associate Professor R. Dabrowski (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Impact of procedural and patient-related risks on 1-year outcomes for patients with 1-month DAPT followed by P2Y12 inhibitor monotherapy after biodegradable-polymer drug-eluting stent implantation
Doctor R. Shimada (Yahaba, JP)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes of risk score-guided dual antiplatelet therapy in patients with acute coronary syndrome who underwent percutaneous coronary intervention
Assistant Professor D. Hyun (Kwang Ju, KR)
Abstract Slides Video
Presentation thumbnail
The comparison of short-term dual antiplatelet therapy versus standard dual antiplatelet therapy in elderly patients with coronary artery disease who underwent percutaneous coronary intervention
Doctor I. Jin (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Data-driven decisions for anticoagulant and antiplatelet therapy

The Event

Event poster

ESC Congress 2024

2 September 2024 11:00 CET
You may be interested in
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
2 September 2024
thumbnail
Congress Presentation
Apixaban vs. warfarin for venous thromboembolism in renal impairment: a meta-analysis of efficacy and safety
31 August 2025
thumbnail
Congress Session
HOT LINE SESSION 8
29 August 2022
thumbnail
Congress Presentation
Long-term real-world outcomes of edoxaban in atrial fibrillation patients with and without prior ischaemic stroke: A 4-year follow-up analysis from ETNA-AF Europe
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources